Rolling Submission to be reviewed by FDA for ublituximab in combination with umbralisib for Chronic Lymphocytic Leukaemia (CLL)

Submission was based on the UNITY-CLL phase 3 trial which is investigating ublituximab (a third generation anti-CD20 monoclonal antibody) and umbralisib (a PI3K delta inhibitor) vs active control (obinutuzumab & chlorambucil) in treatment-naïve and relapsed or refractory CLL.

Biospace Inc.